Skip to content
Flucytosine
Ancobon (flucytosine) is a small molecule pharmaceutical. Flucytosine was first approved as Ancobon on 1982-01-01. It is used to treat aids-related opportunistic infections, aspergillosis, candidiasis, chromoblastomycosis, and cryptococcal meningitis amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
nervous system diseasesD009422
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Ancobon (generic drugs available since 2011-06-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Flucytosine
Tradename
Company
Number
Date
Products
ANCOBONBausch Health CompaniesN-017001 RX1982-01-01
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ancobonNew Drug Application2019-08-20
flucytosineNDA authorized generic2023-03-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aids-related opportunistic infections—D017088—
aspergillosisEFO_0007157D001228B44
candidiasis—D002177B37
chromoblastomycosisEFO_0007207D002862B43.9
cryptococcal meningitisEFO_0007228D016919B45.1
mycoses—D009181B35-B49
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AE: Other antifungals for topical use in atc
— D01AE21: Flucytosine
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AX: Other antimycotics for systemic use in atc
— J02AX01: Flucytosine
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151793166—124
NeoplasmsD009369C80463——13
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CholangiocarcinomaD018281C22.137———9
Stomach neoplasmsD013274EFO_0003897C16—8———8
Liver neoplasmsD008113EFO_1001513C22.022———4
Colonic neoplasmsD003110C1823———4
Rectal neoplasmsD01200423———4
Esophageal neoplasmsD004938C15—3———3
AdenocarcinomaD000230—3———3
Bile duct neoplasmsD001650—1——12
Ovarian neoplasmsD010051EFO_0003893C5611———2
Pancreatic neoplasmsD010190EFO_0003860C25—1———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neoplasm metastasisD009362EFO_00097082————2
Nasopharyngeal neoplasmsD0093031————1
Fallopian tube neoplasmsD0051851————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFLUCYTOSINE
INNflucytosine
Description
Flucytosine is an organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections. It has a role as a prodrug. It is an organofluorine compound, a pyrimidone, an aminopyrimidine, a nucleoside analogue and a pyrimidine antifungal drug. It is functionally related to a cytosine.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(=O)[nH]cc1F
Identifiers
PDB—
CAS-ID2022-85-7
RxCUI4451
ChEMBL IDCHEMBL1463
ChEBI ID5100
PubChem CID3366
DrugBankDB01099
UNII IDD83282DT06 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,045 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ancobon, Flucytosine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
71 adverse events reported
View more details